Amitiza - Sucampo Pharmaceuticals, Inc. - Treatment for Constipation
Amitiza is a selective chloride channel activator for the treatment of chronic idiopathic constipation in adults.Posted: January 2006
Related articles
- FDA Approves Amitiza for Opioid-Induced Constipation - April 23, 2013
- FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) - September 17, 2007
- Sucampo Submits New Drug Application for Lubiprostone, an Investigational Compound for the Treatment of Chronic Idiopathic Constipation - April 1, 2005
Amitiza (lubiprostone) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
